drugset

drugset / Trial / NCT02062190

Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

NCT02062190 ↗

Phase 2 Completed 19 enrolled Federal University of Rio Grande do Sul Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

Timeline

Start: 2014-03
Primary completion: 2015-01
Completion: 2015-05

Publications

Zortea K, Franco VC, Francesconi LP, Cereser KM, Lobato MI, Belmonte-de-Abreu PS. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors. Nutrients. 2016 Jan 29;8(2):73. doi: 10.3390/nu8020073.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Resveratrol	Small molecule	100 mg	Oral

Indications